Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zika Virus Vaccine Hunt Begins Following 4,000 Brazilian Birth Defects

This article was originally published in Scrip

Executive Summary

The pharma industry's (and the media's) interest in Ebola has begun to wane as more affected African countries secure disease-free status from the World Health Organization, but another tropical condition has started to capture headlines – Zika virus (ZIKV), a mosquito transferred disease reportedly responsible for approximately 4,000 child birth defects since Oct. 2015.

You may also be interested in...



Zika Vaccine Timeline: Will It Be Too Little Too Late?

Following the Zika outbreak in Latin America in late 2015, a number of pharmaceutical companies have stepped up their vaccine research efforts against a virus that has now been scientifically determined as the cause of microcephaly and other severe brain defects in babies. But will a product be able to reach the market soon enough to have an impact on the current outbreak?

Numbers Crunched: Reviewing Biopharma's FY 2019 Performance

The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel